Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Buys 5,000 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 5,000 shares of the firm’s stock in a transaction on Monday, July 27th. The stock was purchased at an average cost of $3.44 per share, for a total transaction of $17,200.00. Following the completion of the acquisition, the chief executive officer owned 652,000 shares in the company, valued at approximately $2,242,880. This trade represents a 0.77% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Amit Kumar also recently made the following trade(s):

• On Friday, July 24th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 20th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.46 per share, with a total value of $17,300.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.37 per share, for a total transaction of $10,743.56.
• On Friday, July 10th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.04 per share, for a total transaction of $15,200.00.
• On Friday, June 12th, Amit Kumar acquired 21,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $2.50 per share, for a total transaction of $52,500.00.

Anixa Biosciences Price Performance

Shares of ANIX opened at $3.52 on Wednesday. Anixa Biosciences Inc has a one year low of $2.32 and a one year high of $5.46. The company has a market cap of $119.75 million, a P/E ratio of -11.35 and a beta of 0.59. The firm has a 50 day simple moving average of $2.93 and a two-hundred day simple moving average of $2.92.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. On average, analysts expect that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research raised Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.50.

Institutional Trading of Anixa Biosciences

Several institutional investors have recently modified their holdings of ANIX. Vanguard Group Inc. raised its position in Anixa Biosciences by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock worth $4,694,000 after purchasing an additional 29,436 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Anixa Biosciences by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock valued at $1,095,000 after buying an additional 7,271 shares during the period. Bank of America Corp DE raised its position in shares of Anixa Biosciences by 1.7% during the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock worth $706,000 after acquiring an additional 3,645 shares during the last quarter. State Street Corp raised its position in shares of Anixa Biosciences by 32.0% during the fourth quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after acquiring an additional 38,540 shares during the last quarter. Finally, 683 Capital Management LLC acquired a new position in shares of Anixa Biosciences in the fourth quarter worth approximately $355,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.